Caristo Applauds Abcentra's Successful First Patient Dosing in Phase 2b FORTIFY Trial for Cardiovascular Disease Caristo Diagnostics congratulates Abcentra on the successful dosing of the first patient in the Phase 2b FORTIFY trial, a crucial step in evaluating orticumab for cardiovascular patients.

Caristo Applauds Abcentra's Successful First Patient Dosing in Phase 2b FORTIFY Trial for Cardiovascular Disease #USA #Stamford #Caristo_Diagnostics #Abcentra #Orticumab

Abcentra LLC Initiates Phase 2b Clinical Trial for Orticumab Targeting Cardiovascular Disease Abcentra LLC has initiated its Phase 2b 'FORTIFY' trial, aiming to evaluate orticumab's effectiveness in patients with cardiovascular disease following myocardial infarctions.

Abcentra LLC Initiates Phase 2b Clinical Trial for Orticumab Targeting Cardiovascular Disease #United_States #Los_Angeles #Fortify #Abcentra #Orticumab

Dr. Peter Libby Joins Abcentra Board Amidst Orticumab Trial Phase 2b Euphoria Biotech firm Abcentra appoints renowned cardiologist Dr. Peter Libby to its Board as it embarks on its Phase 2b trial for Orticumab, a promising anti-inflammatory therapy.

Dr. Peter Libby Joins Abcentra Board Amidst Orticumab Trial Phase 2b Euphoria #USA #Los_Angeles #Abcentra #Orticumab #Dr._Peter_Libby